Archive for the ‘faked data’ Category
Want bogus data, million-dollar fraud allegations and a scientist on the lam? We give you Alain Malafosse.
The British Journal of Psychiatry has retracted a June 2013 paper by Malafosse and his colleagues on the genetics of bipolar disorder in children because Malafosse allegedly fabricated key data in the study.
The article, “Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder,” purported to find that people with bipolar disorder who had experienced more, and more severe, abuse early in life were more likely to show epigenetic changes. According to the abstract:
The paper, “The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells,” was initially published in September 2011 and has been cited 25 times, according to Thomson Scientific’s Web of Knowledge. First author Jiyeon Kim was an MD-PhD candidate at the University of Pennsylvania until this year, according to a LinkedIn profile.
Nasser Chegini, an ob-gyn formerly on the faculty at the University of Florida who has been the subject of an Office of Research Integrity (ORI) inquiry for several years, has a second retraction.
Chegini is suspected of having used bogus data in some of his work — research backed in part by some $4 million in federal funding.
It’s also the the fourth retraction for R. K. Singhal, of the University of Rajasthan, Jaipur, India. Behold the notice for “Magnetic behavior of functionally modified spinel Ni0.4Ca0.6Fe2O4 nanoferrite,” in the International Journal of Modern Physics B: Read the rest of this entry »
A year after an ORI report discredited the work of former University of Washington in Seattle researcher Andrew Aprikyan, one of the papers named in the report has finally been retracted.
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013: